Anixa Biosciences (STU:CY71) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CY71 Anixa Biosciences Inc STU:CY71
36 GF Score
Price €2.76
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:CY71 vs BMEA, PMN, ATRA: Short Interest Comparison

For the Biotechnology subindustry, Anixa Biosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anixa Biosciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Short Interest falls into.


STU:CY71
36GF Score
Anixa Biosciences Inc STU:CY71
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Business Description

Other Exchanges ANIX:USA
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
36GF Score

Get the complete analysis for STU:CY71

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price